Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.

Hensel MT, Marshall JD, Dorwart MR, Heeke DS, Rao E, Tummala P, Yu L, Cohen GH, Eisenberg RJ, Sloan DD.

J Virol. 2017 Apr 13;91(9). pii: e02257-16. doi: 10.1128/JVI.02257-16. Print 2017 May 1.

PMID:
28228587
2.

Effects of MF59 Adjuvant on Induction of Isotype-Switched IgG Antibodies and Protection after Immunization with T-Dependent Influenza Virus Vaccine in the Absence of CD4+ T Cells.

Ko EJ, Lee YT, Kim KH, Jung YJ, Lee Y, Denning TL, Kang SM.

J Virol. 2016 Jul 11;90(15):6976-88. doi: 10.1128/JVI.00339-16. Print 2016 Aug 1.

3.

Alum: an old dog with new tricks.

Wen Y, Shi Y.

Emerg Microbes Infect. 2016 Mar 23;5:e25. doi: 10.1038/emi.2016.40. Review.

4.

Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens.

Knudsen NP, Olsen A, Buonsanti C, Follmann F, Zhang Y, Coler RN, Fox CB, Meinke A, D'Oro U, Casini D, Bonci A, Billeskov R, De Gregorio E, Rappuoli R, Harandi AM, Andersen P, Agger EM.

Sci Rep. 2016 Jan 21;6:19570. doi: 10.1038/srep19570.

5.

Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review.

Camilloni B, Basileo M, Valente S, Nunzi E, Iorio AM.

Hum Vaccin Immunother. 2015;11(3):553-63. doi: 10.1080/21645515.2015.1011562. Review.

6.

Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children.

Knuf M, Leroux-Roels G, Rümke H, Rivera L, Pedotti P, Arora AK, Lattanzi M, Kieninger D, Cioppa GD.

Hum Vaccin Immunother. 2015;11(2):358-76. doi: 10.4161/21645515.2014.987014.

7.

Long-term immunogenicity of an inactivated split-virion 2009 pandemic influenza A H1N1 virus vaccine with or without aluminum adjuvant in mice.

Xu W, Zheng M, Zhou F, Chen Z.

Clin Vaccine Immunol. 2015 Mar;22(3):327-35. doi: 10.1128/CVI.00662-14. Epub 2015 Jan 14.

8.

New vaccines against influenza virus.

Lee YT, Kim KH, Ko EJ, Lee YN, Kim MC, Kwon YM, Tang Y, Cho MK, Lee YJ, Kang SM.

Clin Exp Vaccine Res. 2014 Jan;3(1):12-28. doi: 10.7774/cevr.2014.3.1.12. Epub 2013 Dec 18. Review.

9.

Nizatidine, a small molecular compound, enhances killed H5N1 vaccine cell-mediated responses and protects mice from lethal viral challenge.

Wang S, Wu B, Xue J, Wang M, Chen R, Wang B.

Hum Vaccin Immunother. 2014;10(2):461-8. doi: 10.4161/hv.27165. Epub 2013 Nov 19.

10.

Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial.

Rümke HC, Richardus JH, Rombo L, Pauksens K, Plaßmann G, Durand C, Devaster JM, Dewé W, Oostvogels L.

BMC Infect Dis. 2013 Jul 26;13:348. doi: 10.1186/1471-2334-13-348.

11.

Assessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A/H5N1 prepandemic influenza vaccine in adult and elderly subjects.

Bihari I, Pánczél G, Kovacs J, Beygo J, Fragapane E.

Clin Vaccine Immunol. 2012 Dec;19(12):1943-8. doi: 10.1128/CVI.00373-12. Epub 2012 Oct 17.

12.

Effect of adjuvants on responses to skin immunization by microneedles coated with influenza subunit vaccine.

Weldon WC, Zarnitsyn VG, Esser ES, Taherbhai MT, Koutsonanos DG, Vassilieva EV, Skountzou I, Prausnitz MR, Compans RW.

PLoS One. 2012;7(7):e41501. doi: 10.1371/journal.pone.0041501. Epub 2012 Jul 25.

13.

Use of praziquantel as an adjuvant enhances protection and Tc-17 responses to killed H5N1 virus vaccine in mice.

Zou Q, Hu Y, Xue J, Fan X, Jin Y, Shi X, Meng D, Wang X, Feng C, Xie X, Zhang Y, Kang Y, Liang X, Wu B, Wang M, Wang B.

PLoS One. 2012;7(4):e34865. doi: 10.1371/journal.pone.0034865. Epub 2012 Apr 18.

14.

A caprine herpesvirus 1 vaccine adjuvanted with MF59™ protects against vaginal infection and interferes with the establishment of latency in goats.

Marinaro M, Rezza G, Del Giudice G, Colao V, Tarsitano E, Camero M, Losurdo M, Buonavoglia C, Tempesta M.

PLoS One. 2012;7(4):e34913. doi: 10.1371/journal.pone.0034913. Epub 2012 Apr 12.

15.

Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein.

Dey AK, Burke B, Sun Y, Hartog K, Heeney JL, Montefiori D, Srivastava IK, Barnett SW.

Vaccine. 2012 Apr 5;30(17):2749-59. doi: 10.1016/j.vaccine.2012.02.027. Epub 2012 Feb 22.

16.

Structure-activity relationships in toll-like receptor 2-agonists leading to simplified monoacyl lipopeptides.

Agnihotri G, Crall BM, Lewis TC, Day TP, Balakrishna R, Warshakoon HJ, Malladi SS, David SA.

J Med Chem. 2011 Dec 8;54(23):8148-60. doi: 10.1021/jm201071e. Epub 2011 Nov 4.

17.

Safety and immunogenicity of a candidate parvovirus B19 vaccine.

Bernstein DI, El Sahly HM, Keitel WA, Wolff M, Simone G, Segawa C, Wong S, Shelly D, Young NS, Dempsey W.

Vaccine. 2011 Oct 6;29(43):7357-63. doi: 10.1016/j.vaccine.2011.07.080. Epub 2011 Jul 30.

18.

Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine.

Cheong HJ, Song JY, Heo JY, Noh JY, Choi WS, Park DW, Wie SH, Kim WJ.

Clin Vaccine Immunol. 2011 Aug;18(8):1358-64. doi: 10.1128/CVI.05111-11. Epub 2011 Jun 29.

Supplemental Content

Support Center